Literature DB >> 2536631

Hereditary tyrosinemia type I (chronic form): pathologic findings in the liver.

L P Dehner1, D C Snover, H L Sharp, N Ascher, R Nakhleh, D L Day.   

Abstract

Hereditary tyrosinemia type I presents with either acute hepatic failure in the neonatal period or later in infancy with progressive liver dysfunction secondary to cirrhosis. The inevitably fatal outcome in those children with the chronic form has been transformed with the advent of liver transplantation. Native livers from five children who received allografts were studied pathologically and compared with earlier hepatic biopsies in two of these patients that had been performed several years before transplantation. Our findings support the conclusion that a sequence of morphologic changes from the initial micronodular cirrhosis through an intermediate mixed cirrhotic pattern to macronodular cirrhosis occurs. The micronodular phase is transitory, over a period of only a few months, since mixed micronodular macronodular cirrhosis was already present in the livers of children who received transplants by 11 months of age. Focal hepatocellular dysplasia was present in one of the livers with mixed cirrhosis but was not identified in the other two cases. Macronodular cirrhosis accompanied two cases of hepatocellular carcinoma in this study. In order to preclude the latter complication, liver replacement is necessary before the age of 2 years.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2536631     DOI: 10.1016/0046-8177(89)90179-2

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  12 in total

1.  Orthotopic liver transplantation in liver-based metabolic disorders.

Authors:  A P Mowat
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

2.  Epidemiology and carcinogenesis of hepatocellular carcinoma.

Authors:  Trishe Y-M Leong; Anthony S-Y Leong
Journal:  HPB (Oxford)       Date:  2005       Impact factor: 3.647

3.  Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation.

Authors:  F J van Spronsen; G P Smit; F A Wijburg; Y Thomasse; G Visser; H S Heymans
Journal:  J Inherit Metab Dis       Date:  1995       Impact factor: 4.982

4.  Deficient DNA-ligase activity in the metabolic disease tyrosinemia type I.

Authors:  M J Prieto-Alamo; F Laval
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-13       Impact factor: 11.205

5.  DNA ploidy abnormalities in the liver of children with hereditary tyrosinemia type I. Correlation with histopathologic features.

Authors:  C Zerbini; D S Weinberg; K A Hollister; A R Perez-Atayde
Journal:  Am J Pathol       Date:  1992-05       Impact factor: 4.307

Review 6.  Current strategies for the treatment of hereditary tyrosinemia type I.

Authors:  Merja Ashorn; Sari Pitkänen; Matti K Salo; Markku Heikinheimo
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

7.  Visceral pathology of hereditary tyrosinemia type I.

Authors:  P Russo; S O'Regan
Journal:  Am J Hum Genet       Date:  1990-08       Impact factor: 11.025

Review 8.  Tyrosinaemia type I--an update.

Authors:  E A Kvittingen
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

Review 9.  Treatment of inherited metabolic disorders by liver transplantation.

Authors:  M Burdelski; B Rodeck; A Latta; K Latta; J Brodehl; B Ringe; R Pichlmayr
Journal:  J Inherit Metab Dis       Date:  1991       Impact factor: 4.982

10.  Case of hepatocellular carcinoma in a patient with hereditary tyrosinemia in the post-newborn screening era.

Authors:  Essam M Imseis; John S Bynon; Chad Thornhill
Journal:  World J Hepatol       Date:  2017-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.